Clinical approach to kidney disease in kidney recipients in Spain
Por:
Campistol JM, Gutiérrez-Dalmau A, Crespo J, Saval N, Grinyó JM and Grupo de Estudio Observa
Publicada:
1 may 2015
Categoría:
Nephrology
Resumen:
Background and objectives: In the present study, clinical criteria used by Spanish nephrologists when approaching chronic kidney disease (CKD) in kidney recipients, as well as their level of maintenance and control of renal function, were evaluated.
Methods: An epidemiological, observational, multicenter, nation-wide, prospective study was carried out, with a 6-month follow-up period. Three hundred and sixty-eight adult patients with stage 3 kidney disease after a 24-month or longer post-transplantation follow-up period were included. Visits schedule included a retrospective visit, a baseline visit, an optional mid-term visit, and a final visit at month 6.
Results: Mean time since kidney transplantation was 8.2 +/- 5.4years. Most common pre-transplant cardiovascular risk factors were high blood pressure (80.2%), followed by high cholesterol levels (61.7%). Serum creatinine levels showed a statistically significant decrease from baseline visit to 6-month visit (0.06 +/- 0.22; P < .0001), and glomerular filtration rate (GFR) reduction was -1.03 +/- 6.14 (P = 0.0014). Significant independent prognostic factors for GFR worsening were: higher 24-hour proteinuria (OR = 1.001 per mg; P = .020), longer time since transplantation (OR= 1.009 per month; P = .017), and lower hemoglobin levels (OR = 1.261 per g/dl; P = .038). Donor age also had some negative influence (OR = 1.021 per year; P = .106). Biopsies were obtained in only 8% of kidney transplant recipients with stage 3 CKD with an intervention being carried out in 25.4% of cases.
Conclusions: Secondary markers and factors resulting in CKD progression, particularly anemia, are still frequently uncontrolled after kidney transplantation. Only about 2% of patients benefit from a therapeutic intervention based on a biopsy. Clinical perception differs from objective measures, which results in an obvious clinical inertia regarding risk factor control in such patients. (C) 2015 The Authors. Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Nefrologia.
Filiaciones:
Campistol JM:
Unidad de Nefrología y Trasplante Renal, Hospital Clínic, Barcelona, España
Gutiérrez-Dalmau A:
Servicio de Nefrología, Hospital Miguel Servet, Zaragoza, España
:
Servicio de Nefrología, Hospital Universitario Dr. Peset, Valencia, España
Saval N:
Novartis Farmacéutica S.A., Barcelona, España
Grinyó JM:
Unidad de Nefrología y Trasplante Renal, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, España.
Open Access
|